Financial releases

Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand

Appointment of Daniel Teper to the Crossject Supervisory Board - Building skills to support the US transition

2022 Annual Results

Further strengthening of the financial structure

Big improvement in the Gaïa social and environmental rating

Clinical demonstration of ZENEO® efficiency for intramuscular injection of midazolam

First-half 2022 results Achievement of major milestones in the first half On track for a change of dimension

Interest for the ZENEO® auto-injector from an American pharmaceutical company

Safe, fast and effective use of ZENEO® Midazolam validated by a new human factors study in the United States

Great success of the exercise of warrants